ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVGN Evogene Ltd

0.659499
0.0034 (0.52%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Evogene Ltd NASDAQ:EVGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0034 0.52% 0.659499 0.60 4.99 0.669 0.64 0.6551 54,246 05:00:10

Evogene Schedules First Quarter 2024 Financial Results Release

09/05/2024 12:00pm

PR Newswire (US)


Evogene (NASDAQ:EVGN)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Evogene Charts.

Zoom conference call scheduled for 9:00 AM ET

REHOVOT, Israel, May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.

Evogene Logo

Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_GBxR-LTZRYy9D7OIt2YW0g

The entire conference will be available online on the company's website a few days after.

About Evogene:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines - MicroBoost AIChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:

  1. Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
  2. Lavie Bio Ltd. (www.lavie-bio.com) -  developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
  3. AgPlenus Ltd. (www.agplenus.com) -  developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
  4. Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.

For more information, please visit: www.evogene.com.

Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901

Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/evogene-schedules-first-quarter-2024-financial-results-release-302141103.html

SOURCE Evogene

Copyright 2024 PR Newswire

1 Year Evogene Chart

1 Year Evogene Chart

1 Month Evogene Chart

1 Month Evogene Chart

Your Recent History

Delayed Upgrade Clock